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Abstract This study seeks to provide a review of the clinical
data published as of July 2011 concerning the postsurgical
adhesion barrier, Seprafilm (chemically modified hyaluronic
acid and carboxymethylcelulose; Genzyme Corporation,
Cambridge, MA). Included articles detail the application
of Seprafilm for intraabdominal uses that have been
approved (on-label) and those considered investigational
(off-label) by the FDA. Medline and EMBASE Drugs
and Pharmaceuticals databases were searched for all
original clinical Seprafilm research published as of July
2011. All human Seprafilm intraabdominal clinical
reports and studies, excluding those related to prosthetic
mesh were included. Data extraction involved the sys-
tematic review of each article. The data synthesis is the
summary of Seprafilm human intraabdominal clinical
reports and studies describing safety and/or efficacy.
The safety and efficacy of Seprafilm in reducing post-
operative adhesions has been clearly demonstrated in
abdominal and pelvic laparotomy. While reports have
described the safe and successful use of Seprafilm following
laparoscopy, pediatric laparotomy, and in patients with malig-
nancy and/or infection, the safety and efficacy of Seprafilm
use in these procedures has not been definitively established in
randomized controlled trials.
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Introduction
Seprafilm adhesion barrier is a bioresorbable membrane
composed of chemically modified sodium hyaluronate
(HA) and carboxymethylcellulose (CMC). The absorbable
adhesion barrier received FDA market approval in 1996 and
is available worldwide. To date, over two million patients
have been treated with Seprafilm. The product is indicated
for use in adult patients undergoing abdominal or pelvic
laparotomy and is intended to reduce the incidence, extent,
and severity of postoperative adhesions between the abdom-
inal wall and omentum, small bowel, bladder, and stomach;
and between the uterus and tubes, ovaries, large bowel, and
bladder [1]. Postsurgical adhesions are also known to be a
source of complications following abdominal and pelvic
laparoscopy [2], pediatric procedures as well as in surgical
patients with infections and malignancy. Consequently,
Seprafilm has been used and studied “off-label,” at the
discretion of individual surgeons, following many of these
types of surgeries.
In an attempt to improve upon the outcomes achievable
through the use of good surgical technique, anti-adhesion
adjuvants have been introduced. This article intends to sum-
marize the available research, as of July 2011, for one such
adjuvant: Seprafilm Adhesion Barrier (Genzyme, Cambridge,
MA) following abdominal and pelvic procedures considered
both “on” and “off-label.”
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Clinical safety and efficacy studies
For over 15 years, Seprafilm’s effect on adhesion develop-
ment has been evaluated in men, women, and children by
multiple clinical investigators. The reported results of these
studies have largely shown, often at repeat surgery, that
Seprafilm is effective in reducing adhesion development or
has led to another beneficial outcome. An overview of these
published clinical reports is provided in Table 1.
Uses of Seprafilm following abdominopelvic surgery
The safety and efficacy of Seprafilm in abdominopelvic lapa-
rotomy were initially evaluated in two randomized controlled
multicenter clinical trials. In one investigation, 183 patients
with ulcerative colitis and familial polyposis undergoing colec-
tomy with ileal pouch anal anastomosis and temporary loop
ileostomy were enrolled [3]. The incidence, extent, and
severity of adhesions to the underside of the abdominal
wall incision were evaluated at the time of ileostomy
closure. Absence of adhesions was seen in 51% of Seprafilm
treated patients, while only 6 % of control patients had no
adhesions (p<0.00000000001). Dense adhesions were ob-
served in 58 % of control patients but in only 13 % of the
Seprafilm treated patients (p<0.0001). There was no statisti-
cally significant difference observed between the incidence of
adverse events in the Seprafilm and control groups (p>0.05)
[3]. The most common side effects noted in the Seprafilm and
control groups, respectively, were small bowel obstruction
(9 % and 10 %), abscess (8 % and 2 %), nausea/vomiting/
diarrhea (4 % and 5 %), pulmonary embolism (4 % and 0 %),
deep venous thrombosis (2 % and 1 %), ileus (2 % and 1 %),
fever (2 % and 0 %), and adrenal insufficiency (2 % and 0 %).
In a second multicenter, randomized trial, 127 women
undergoing uterine myomectomy were included [4]. Patients
were randomly assigned to receive the application or no
application of Seprafilm to the anterior and posterior surfaces
of the uterus following the myomectomy via laparotomy.
Postoperative adhesion formation was evaluated during a
second look laparoscopy performed an average of 23 days
later. The mean number of abdominopelvic locations adherent
to the uterus was significantly less in the Seprafilm group
[4.98 (n049)] as compared with the control group [7.88
(n048)] (p<0.0001). In addition, patients in the Seprafilm
group had a significant reduction in the severity of adhe-
sions (p<0.01), the extent of adhesions (p<0.01), and the
area of uterus involved in the adhesions (p<0.02). There
was no statistically significant difference in the occurrence
of adverse events between the treatment and control groups.
Further, no adverse event was considered to be definitely
related to Seprafilm.
Subsequently, the comparative efficacy of Seprafilm use
in abdominal laparotomies was evaluated in a series of 30
patients undergoing colectomy [5]. The incidence of
adhesions at Seprafilm treated sites was 36.7 % as com-
pared to 63.3 % in the control sites within the same
patient (p<0.05). A comparison of this group of Sepra-
film treated patients to a historical control that underwent
abdominal laparotomy without Seprafilm showed that the
incidence (p<0.05) and severity (p<0.01) of adhesions
were lower in the Seprafilm group as compared to the historical
controls.
In a series of individuals undergoing Billroth I anasto-
mosis following distal gastrectomy, postoperative small
bowel obstruction was examined in the absence (n0169)
or presence (n0113) of Seprafilm use [6]. Adhesive related
obstructions were significantly less in patients treated with
Seprafilm, with rates of obstruction within the first 2 years
of surgery being over sixfold higher (0.9 % with Seprafilm
as opposed to 6.5 % without Seprafilm).
A large (N01,791), post-marketing, randomized, controlled-
trial in patients undergoing laparotomies for small bowel
obstruction, inflammatory bowel or diverticular disease
was conducted to further evaluate the incidence of abscess,
pulmonary embolism and foreign body reaction and the pre-
vention of adhesive small bowel obstruction following Sepra-
film use [7, 8]. Results from this trial demonstrate that
compared to the no treatment control, Seprafilm treatment
reduced the relative risk of a first adhesive small bowel
obstruction by 47 % (1.8 % vs. 3.4 %, treatment vs. control,
respectively, p00.044) in colorectal patients, where the out-
come was verified by direct visualization [8]. Seprafilm treat-
ment was found to have no effect on small bowel obstructions
in which reoperation and direct visualization was not per-
formed. There were no reports of foreign body reactions.
Additionally, no relationship was observed between Seprafilm
and the incidence of pulmonary embolus. However, a retro-
spective post hoc analysis suggested that wrapping Seprafilm
around a newly created anastomosis was associated with a
statistically significant increase in anastomotic leak related
adverse events (fistula, leak, abscess, peritonitis, and sepsis).
Based upon this data, the Seprafilm labeling has been updated
to advise against wrapping Seprafilm directly around a newly
created anastomotic suture or staple line. A multivariate anal-
ysis of factors that might affect the incidence of leak related
events showed that wrapping of Seprafilm, lower body mass
index, use of steroids, and preexisting abscess were predictors
of leak related events. The increase in risk of leak related
events with wrapping of Seprafilm [odds ratio, 2.7, 95 %
confidence interval (1.8, 4.0)] was similar to the risk associ-
ated with the use of steroids [odds ratio, 1.9, 95 % confidence
interval (1.3, 2.7)].
In another study, among 121 subjects undergoing intesti-
nal resection, who received Seprafilm beneath the midline
incision, 11 (9.1 %), developed postoperative ileus, with a
mean time of onset of 16.1±12.1 days [9]. In a subgroup
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Table 1 Clinical publications and calculated effect size
Reference N Therapeutic area Favorable seprafilm outcome Effect sizea Reported p value
Becker et al. [3] 183 Abdominal Incidence 17.4 <0.00000000001
Incidence of fewer dense adhesions 7.6 <0.0001
Incidence of fewer moderate adhesions 16.5
Incidence of greater mild adhesions 8.5
Extent 1.2 <0.001
Fukushima et al. [5] 30 Abdominal Comparison to untreated control site
Incidence of adhesions 3.0 0.05
Incidence of more grade 1 3.3 0.05
Incidence of fewer grade 3 2.1
Comparison to pts with previous laparotomy
Incidence of adhesions 3.6 0.05
Incidence of more grade 1 9.0 0.01
Incidence of fewer grade 3 3.5
Salum et al. [14] 538 Abdominal Incidence of intestinal obstruction 1.5 NS








Incidence of pelvic adhesions 3.0 0.41
Incidence of adhesions superior segment 2.1 0.48
Incidence of adhesions middle segment 8.0 0.09
Incidence of adhesions inferior segment 3.0 0.28
Median severity score entire incision Cannot be calculated
—only range reported
0.002
Tang et al. [27] 181 Abdominal Overall mean 4 quadrant adhesion score Phase I −0.06 NS
Overall mean 4 quadrant adhesion score Phase II 0.8 0.02






Resumed liquid diet sooner 0.6 NS
Resumed solid diet sooner 0.5 NS
Mohri et al. [16] 367 Abdominal Incidence of early postoperative
small bowel obstruction
2.4 0.02
Reoperation for early postoperative
small bowel obstruction
2.7 NS
Fazio et al. [8] 1791 Abdominal Incidence of operative adhesive
small bowel obstruction
1.9 0.044
Incidence of all cause bowel obstruction 1.0 NS
Salum et al. [28] 191 Abdominal Incidence of grade 0 adhesions midline
and stoma
4.3 0.021
Incidence of grade 0 adhesions midline 3.1
Incidence of greater grade 1 adhesions
midline and stoma
2.0 0.096
Incidence of greater grade 1 adhesions midline 1.1
Incidence of fewer grade 3 adhesions
midline and stoma
2.56




Incidence of enterotomy/myotomy midline 0.8
Fujii et al. [9] 115 Abdominal Incidence of adhesion related post-op ileus 1.0 NS
27 Incidence of adhesions 11.6 0.0004
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Table 1 (continued)
Reference N Therapeutic area Favorable seprafilm outcome Effect sizea Reported p value
Van der Wal
et al. [31]
35 Abdominal Incidence of chronic abdominal complaints 4.7 0.018






156 Abdominal Oncologic Recurrence rate 1.8 NS
1 year survival 1.2 NS
2 year survival 2.3 NS
Kusonoki et al.
[36]
62 Abdominal Oncologic Incidence of intestinal obstruction prior
to ileostomy closure
2.2 0.60
Incidence of intestinal obstruction
following ileostomy closure
2.9 0.22
Incidence of grade 0 adhesions midline 40.6
Incidence of grade 0 adhesions stoma Cannot be calculated
—0 events in control
group
5 year survival 1.6
Uchida et al. [32] 278 Abdominal Oncologic No control group n/a n/a
Hayashi et al. [37] 144 Abdominal Oncologic Incidence of small bowel obstruction 1.7 NS
Park et al. [38] 427 Abdominal Incidence of early postoperative
bowel obstruction
2.7 NS
Oncologic Incidence of readmission for early
postoperative bowel obstruction
1.7 NS
Khaitan et al. [20] 19 Abdominal
laparoscopy















Ileostomy take down time Cannot be calculated 0.023






Incidence of 2-year adhesive
postoperative bowel obstruction
7.8 0.021
Klinger et al. [45] 1 Abdominal Case report n/a n/a
Trickett et al. [46] 4 Abdominal Case report n/a n/a
Remzi et al. [47] 3 Abdominal Case report n/a n/a
David et al. [48] 1 Abdominal Case report n/a n/a
Tyler et al. [49] 3 Abdominal Case report n/a n/a
Mizuno et al. [39] 9 Pediatrics abdominal No control group n/a n/a
Ong et al. [40] 3 Pediatrics abdominal No control group n/a n/a
Inoue et al. [41] 122 Pediatrics abdominal Incidence of adhesions 6.7 0.007
Incidence of greater grade 1 adhesions 12.8 0.0009
Reoperative time 1.1 0.04
Blood loss≥3 g/kg Cannot be calculated 0.09
Blood loss<3 g/kg —no SD or SEM
reported
Winfield et al. [42] 18 Pediatric abdominal No control group n/a n/a
Fushiki et al. [43] 52 Obstetrics Incidence of adhesions 11.5 0.001
Operative time to delivery Cannot be calculated—
only range reported
0.014
Operative time total Cannot be calculated—
only range reported
0.009
Blood loss Cannot be calculated—
only range reported
0.134
Severity of adhesions Cannot be calculated—
only range reported
0.001
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who underwent a repeat surgical procedure, sites at which
Seprafilm was placed beneath the anterior abdominal wall,
had a lower incidence of adhesions (11/27, 40 %) as com-
pared to untreated sites (24/27, 88.9 %, p00.0004).
A recent report purported to summarize the outcome of
4203 patients by way of a meta-analysis [10]. The authors
concluded that Seprafilm use decreased intraabdominal
adhesions after general surgical procedures, but did not
reduce postoperative bowel obstruction, and was associated
with increased intraabdominal abscess and bowel anasto-
motic leaks. Three letters to the Editor were subsequently
published which criticized the methodology used for the
Table 1 (continued)
Reference N Therapeutic area Favorable seprafilm outcome Effect sizea Reported p value
Diamond et al. [4] 127 Gynecologic Mean number of sites adherent to the uterus 0.8 <0.0001
Severity 0.5 <0.01
Extent 0.4 <0.01
Tsuji et al. [44] 63 Gynecologic Incidence of uterine adhesions
compared o no treatment control
20 0.0003
Incidence of uterine adhesions
compared to Dextran 40
14.4 0.0004
Incidence of uterine adhesions
compared to Beriplast
18 0.0005
Incidence of peritoneal adhesions
compared to no treatment control
13.5 0.001
Incidence of peritoneal adhesions
compared to Dextran 40
2.5 0.2557
Incidence of peritoneal adhesions
compared to Beriplast
4.3 0.0818
Incidence of adnexal adhesions
compared to no treatment control
72 <0.0001
Incidence of adnexal adhesions
compared to Dextran 40
6.8 0.0098
Incidence of adnexal adhesions
compared to Beriplast
1.2 0.855
AFS Score compared to no
treatment control
1.5 <0.0001
AFS Score compared to Dextran 40 0.9 0.0223
AFS Score compared to Beriplast 0.3 0.8208
Takeuchi et al. [21] 114 Gynecologic
laparoscopy
No control group n/a n/a
Chuang et al. [22] 127 Gynecologic
laparoscopy





Feasibility study n/a n/a
Lipetskaia et al. [26] 171 Gynecologic
laparoscopy
Feasibility study n/a n/a
Bristow et al. [33] 21 Gynecologic Oncologic Mean pelvic adhesion score versus
mean abdominal adhesion score
(internal control)
1.9 0.002
Mean pelvic adhesion score versus mean
pelvic adhesion score (historical control)
1.7 0.004
Bristow et al. [50] n/a Gynecologic Oncologic No control group—cost effectiveness n/a n/a
Tan et al. [34] 202 Gynecologic Oncologic 5 year disease free survival 0.6 NS
5 year overall survival 0.6
30 day bowel obstruction 3.4
Leitao et al. [17] 423 Gynecologic Oncologic Incidence of intraabdominal collections 0.3 0.0009
Tabata et al. [18] 371 Gynecologic Oncologic Incidence of early postoperative small bowel
obstruction
5.0 <0.05
Incidence of surgical site infection 2.0 NS
a For continuous outcomes, effect size is the (control group mean − the Seprafilm mean) divided by the pooled standard deviation for the 2 groups
[ES0(M1−M2)/pooled SD], and for binomial outcomes, effect size is the odds ratio or the ratio of the odds of a success for the Seprafilm group to
the odds of a success for the control group [ES 0 (ad)/(bc)]
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meta-analysis. The deficits noted were that the authors
included patients in the Seprafilm group that were treated
with a different adhesion product, the 4,203 patients in-
cluded represented an extremely diverse population of
patients and surgical procedures, the data on effectiveness
in reducing SBO included adverse event reporting and a
definition of SBO which included paralytic ileus, and a
failure to include published reports on the appropriate use
of Seprafilm [11–13]. Two of the letters also reported
potential errors in data abstraction from the initial publications
[11, 13].
Small bowel obstruction
In a retrospective cohort study, the incidence of small bowel
obstruction and enterolysis after Seprafilm use was com-
pared to the incidence in a matched group of historical
controls who did not receive Seprafilm [14]. A trend was
noted in favor of the Seprafilm-treated patients regarding the
incidence of small bowel obstruction (4.6 % in the Sepra-
film group; 6.7 % in the control group, p 0 ns) and enter-
olysis for obstruction (1.5 % in the Seprafilm group; 3.9 %
in the control group, p 0 ns).
In another study, Seprafilm was evaluated in 51 patients
undergoing transabdominal aortic aneurysm surgery [15].
The authors reported that placement of Seprafilm over the
anterior surface under the midline incision (n021) was
associated with a significantly lower rate of postoperative
small bowel obstruction, 0 %, when compared to a no
treatment control group (n030), 20 % (p<0.05).
In a retrospective study of 367 patients who had
undergone elective gastrointestinal laparotomy, Sepra-
film was reported to significantly lower the incidence
of early postoperative bowel obstruction (EPSBO) when
compared to matched controls [16]. One hundred
eighty-four Seprafilm patients were compared with 183
no treatment patients. The incidence of EPSBO was
6.5 % in the treatment group versus 14.2 % in the
control group. Surgical site infection rates were similar in both
groups.
In a retrospective cohort study of 423 women with gyne-
cologic malignancies undergoing a laparotomy (Seprafilm,
n0219; control, n0204), there was no significant difference
in the number of subjects with a small bowel obstruction or
in the incidence of women who required a repeat operation
for a small bowel obstruction [17]. However, there was a
higher rate of intraabdominal fluid collection among Sepra-
film treated subjects (4.1 %) as compared to controls
(0.5 %, p<0.02). In subgroup analysis, this difference was
primarily attributable to women who underwent large bow-
el resection; there was no significant difference in the rates
of intraabdominal fluid collection among women without
large bowel resection.
In another report, a comparison of early postoperative small
bowel obstruction in women who had placement of Seprafilm
at the conclusion of surgery for gynecologic malignancies was
compared with a historical control group [18]. Seprafilm use
was associated with a significantly reduced rate of early small
bowel obstruction as compared to the control group (6/191,
3.1 % vs. 25/180, 13.9 %, respectively, p<0.05). Logistic
regression analysis demonstrated Seprafilm use and conduct
of pelvic lymphadenectomy as independent indicators of a
reduction in early small bowel obstruction. These authors also
reported that Seprafilm use was not associated with an in-
creased risk of postoperative surgical infections (3.6 % vs.
6.7 % incidence, respectively).
Laparoscopic surgery
Although not approved in the USA for laparoscopic use,
Seprafilm has been used laparoscopically in a case series of
19 patients suffering from chronic abdominal pain that un-
derwent laparoscopic adhesiolysis with placement of Sepra-
film [19, 20]. At an average follow-up of 9.6 months, 14
patients discontinued pain medication, 2 were taking
NSAIDS, and 3 needed round the clock narcotics. One
patient underwent a diagnostic laparoscopy 6 months after
Seprafilm placement, and no adhesions were found.
Six additional publications have detailed methods of lapa-
roscopic delivery of Seprafilm; the initial three studies deliv-
ered the intact Seprafilm barrier, while the three others
described endoscopic delivery of a Seprafilm slurry. The first
study published in 2006 describes the safe and efficient lapa-
roscopic placement of the intact Seprafilm barrier in 114
patients undergoing myomectomy with a “purpose-built in-
troducer” [21]. A second paper details laparoscopic Seprafilm
placement in 127 gynecologic patients by way of rolling the
membrane into a cylinder and subsequent placement through
a 10 mm trocar sleeve [22]. A third publication describes a
“flag” technique for Seprafilm placement in 8 patients under-
going laparoscopic abdominal surgery [23]. Other laparoscop-
ic publications detail the creation of a slurry with the
Seprafilm barrier. A Seprafilm slurry has been created by
mixing 20 cc of sterile saline per 13×15 cm sheet of Seprafilm
by one group, with back-loading into a leur lock syringe for
delivery through a laparoscopic irrigator [24]. Fifteen patients
undergoing gynecologic procedures were treated in this fash-
ion with adherence noted to tissue including dependent surfa-
ces and the anterior abdominal wall. The authors noted no
adverse events which were related to Seprafilm or to laparo-
scopic application of the slurry. In similar reports, other
authors [25, 26] described use of warm saline to create the
slurry, with the Seprafilm solution placed in a Toumey syringe
with a Robinson catheter, with the distal top cut off attached to
the syringe, and then put through a laparoscopic trocar port for
intraperitoneal delivery. A laparoscopic grasping instrument
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was utilized to direct or guide the catheter tip to the desired
intraperitoneal sites for laparoscopic application [25, 26].
Closure of defunctioning loop ileostomy
In a prospective randomized study, application of Seprafilm
around the limbs of a defunctioning loop ileostomy was
found to reduce peristomal adhesions and to facilitate early
stomal closure at 3 weeks with minimal complications [27].
A comparison of peristomal adhesions at closure between
the Seprafilm and control groups at 3 weeks, showed that
the Seprafilm group had a significant reduction in the over-
all mean adhesion scores as compared to the control group
(5.81±0.5 vs. 7.82±0.6, respectively; p00.02 ). The number
of patients with dense adhesions was also reduced in the
Seprafilm group as compared to the control group. However,
there was no statistically significant difference in the time
taken, or difficulty encountered, during ileostomy closure in
the groups. However, a trend for easier closure was observed
in the Seprafilm group.
Another study assessed the incidence and severity of
adhesions around a loop ileostomy and analyzed the length
of time and morbidity associated with mobilization and
closure of the ileostomy, with and without the use of Sepra-
film [28]. A total of 191 patients with loop ileostomies were
randomly assigned to either receive Seprafilm under the
midline incision and around the stoma (Group I), only under
the midline incision (Group II), or neither (Group III). At
ileostomy closure, adhesions were graded and operative
morbidity assessed. Significantly more untreated patients
(Group III) had adhesions around the stoma than those
who received Seprafilm treatment of the midline incision
and stoma (Group I; 95.2 % vs. 82.3 %, p00.021). Mean
operative times per treatment group were 27, 25, and
28 min, respectively (p00.38). There was no significant
difference in the number of patients needing myotomy or
enterotomy (29, 27 and 24 patients, respectively), nor in the
number of postoperative complications (7, 9 and 7 patients,
respectively).
In a recent report, “Sushi roll” wrapping of the ileostomy
proximal and distal limbs and covering of the corresponding
mesentery was performed in 18 subjects [29]. Comparing
with a control group of 18 subjects, those in whom Sepra-
film was utilized had a significant reduction in the time
required for ileostomy closure at the subsequent procedure
(107 vs. 121 min, respectively; p00.023).
Infection
In a published prospective, randomized clinical study evalu-
ating the use of Seprafilm in the presence of peritonitis,
Seprafilm reduced the severity but not the incidence of adhe-
sions [30]. Abnormal postoperative wound healing was seen
in 8/21 patients in the Seprafilm group and 3/21 patients in the
control group. In the Seprafilm group, 4 patients had mild to
moderate wound infection, 2 had abscesses related to the
midline, and 2 had wound dehiscence. In the control group,
three patients had abscesses. A publication on the long-term
follow-up of 35 of these patients (16 Seprafilm and 19 control
patients) reported that the incidence of chronic abdominal
complaints (pain, nausea, obstipation) was significantly lower
in Seprafilm patients when compared to control patients [31].
There was no difference in the incidence of small bowel
obstruction between the groups (Seprafilm00 patient;
control02 patients).
An additional study of Seprafilm in presence of infec-
tion was conducted on a cohort of 278 consecutive
patients, who had undergone radical surgery for colorectal
cancer with the placement of Seprafilm under the midline
incision. There was no increase in the rate of septic
conditions nor was there aggravation of postoperative
inflammatory responses reported [32].
Malignancy
In a prospective clinical study, 14 women undergoing pri-
mary cytoreductive surgery with radical oophorectomy for
locally advanced epithelial ovarian cancer received Sepra-
film in the pelvic cavity [33]. The abdominal wall incision
which did not receive Seprafilm served as control. A statis-
tically significant decrease in mean adhesion scores and the
areas involved with adhesions was noted in Seprafilm-
treated sites when compared to control sites. There were
no instances of anastomotic leak and no perioperative com-
plications attributable to the treatment with Seprafilm. Only
one patient had positive biopsy results indicating persistence
of cancer.
Tan et al. examined whether Seprafilm altered cancer
survival in women undergoing surgery for primary perito-
neal, ovarian, and fallopian tube malignancies [34]. They
suggest a need for such a study was based on reports that
hyaluronan may promote tumor growth. Among 202 wom-
en, prospectively followed with a median follow-up of
2.1 years, 139 achieved a disease free interval. The authors
reported that in comparing those who received Seprafilm (n0
88) versus those that did not (n0122), there was no difference
in overall survival, disease free survival, or the rate of imme-
diate postoperative complications.
A retrospective chart review of 156 patients who had
curative surgery for non-metastatic colorectal cancers, found
no difference in 1- and 2-year disease-free survival among the
patients who were administered Seprafilm (88 % and 85 %,
respectively) when compared to patients who did not receive
any Seprafilm (85 % and 72 %), p00.44 [35]. After an
average follow up of 11.4 months, there was no significant
difference between the incidence of peritoneal carcinomatosis,
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recurrence of tumor, or elevation of carcinoembryonic antigen
between the two groups.
Seprafilm was reported to reduce adhesions to the midline
and stoma and have no adverse effect on oncologic outcome
in patients, treated with chemo and radiation therapy, follow-
ing radical resection of rectal carcinoma [36]. Thirty-two
patients were treated with Seprafilm and 30 received no treat-
ment following their colon resection. Seprafilm significantly
reduced the severity and extent of adhesions to the stoma and
midline incision which was associated with reduced surgical
time, blood loss and the extent of the incision required at
ileostomy closure. Seprafilm was not associated with any
postoperative complications and did not affect recurrence or
survival rates.
A randomized trial was conducted in 144 patients who
underwent gastrectomy in whom two sheets of Seprafilm
were placed between the abdominal wall and the small
bowel (n070) or were not (n074) [37]. Seprafilm use was
associated with a non-significant reduction in the overall
incidence of small bowel obstruction (5.7 % versus 9.5 %
in the control group), as well as a non-significant reduction
in the cumulative incidence of obstruction of the small
bowel (6.2 % vs. 12.2 % in the control group at 36 months).
There was no difference in the rates of postoperative com-
plications (32.7 % vs. 39.7 %, respectively) nor was there an
identified effect on intestinal, liver, or kidney function.
In another recent study to examine reduction of adhesive
bowel obstruction following surgery for colorectal cancer,
427 subjects were randomized to receive (n0185) or not to
receive (n0242) one piece of Seprafilm over the denuded
pelvic inlet [38]. Bowel obstruction was defined as the
presence of nausea, vomiting, and abdominal distention, in
combination with a radiologic obstructive bowel pattern.
There was no difference in the clinicopathologic parameters
or non-obstructive complications between the two groups.
However, the incidence of early postoperative small bowel
obstruction was less in the Seprafilm treated subjects than in
the controls (2.7 % vs. 7.0 %, respectively, p00.045). A
similar trend which did not reach significance was identified
in the later postoperative follow-up period (2 % vs. 4.6 %,
respectively).
Pediatric laparotomies
In a case series of nine pediatric patients (age range, 25 days
to 8 years; mean age, 1.7 years), Seprafilm was used in 10
laparotomies [39]. No significant difference was observed in
the hematological parameters and renal and hepatic function
tests. Only one patient developed an adverse event (ileus)
that was managed conservatively. One patient who under-
went a second laparotomy had no adhesion at the site of
placement of Seprafilm. Another case series of 4 children
(ages 57 days to 8 years) reported on Seprafilm use in
pediatric patients for a variety of hepatobiliary conditions
[40]. No adverse events were noted in any of these patients.
One patient (age 57 days) who underwent a second laparot-
omy had no adhesion in the area where Seprafilm was
applied.
In a randomized cohort study in 122 pediatric patients
Seprafilm was reported to safely and effectively reduce the
incidence and severity of adhesions under the midline inci-
sion [41]. Patients were randomized, following laparotomy,
to either receive Seprafilm placement under the midline
incision (n067) or no treatment (n055). In the Seprafilm
group, 18 patients required a planned second laparotomy
and 4 of the 18 required a third procedure. Seprafilm was
applied during each repeat procedure. In the control group,
13 of 55 patients required a planned second laparotomy and
4 of these patients required a third. Efficacy comparisons
were conducted on the 18 Seprafilm patients versus the 13
control. At second surgery, 59.1 % of Seprafilm patients had
no adhesions versus 17.6 % in the control group. Severity
scores were also lower in the Seprafilm treated patients
versus the control group. Seprafilm patients’ severity scores
did not change between the second and third surgeries. In a
retrospective report of 18 pediatric laparotomy patients (25–
18 years), no patients experienced small bowel obstruction,
intraperitoneal abscess or a localized inflammatory reaction
following Seprafilm use. Seprafilm was reported to be suc-
cessfully used without complications [42].
Obstetrics and gynecologic procedures
Cesarean section Use of Seprafilm for preventing adhesions
during cesarean section was evaluated in women undergoing
repeat cesarean section who had received Seprafilm during the
previous cesarean section (n06) and compared to womenwho
had not (n022) [43]. None of the patients who had received
Seprafilm showed any adhesions at the time of repeat cesarean
section while 54.5 % of the control women did. The duration
of surgical procedure and the amount of blood loss did not
differ between the two groups; however, a trend was noted in
favor of Seprafilm for the duration of time between the start of
procedure and the delivery of the baby [an average 4.5 min
(range, 3–6 min) in the Seprafilm group and 6.4 min in the
control group (range: 2–10 min)] p00.057.
Myomectomy In 63 gynecological patients undergoing myo-
mectomy, Seprafilm was reported to have the lowest inci-
dence of uterine and peritoneal adhesion formation and AFS
scores when compared to all anti-adhesion materials tested
[44]. Seprafilm treated patients (n021) were compared to
Dextran 40 (n017) patients, factor 13 with fibrinogen (Beri-
plast) treated patients (n012), and no treatment control (n0
13). Uterine adhesions were present in 14 % of the Seprafilm
patients, 71 % of the Dextran 40 patients, 75 % of the
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Beriplast patients and 77 % of the no treatment control
patients (p≤0.0005). Seprafilm was reported to be more ef-
fective in preventing serosal uterine adhesions following myo-
mectomy than all the other interventions tested.
Possible adverse effects
Published case reports have described the appearance of a
foreign body reaction coincident with the use of Seprafilm.
The first case was a 69-year-old man who underwent laparot-
omy with the placement of Seprafilm and became febrile
12 days after surgery [45]. An exploratory laparotomy
revealed an intense inflammatory reaction under the midline
incision, which on biopsy contained foreign body granulomas.
The patient received steroids and antibiotics after surgery and
made a full recovery. The second case was a 71-year-old
woman with 4 previous abdominal surgeries, who underwent
laparotomy with Seprafilm placement [46]. The patient devel-
oped obstructive symptoms and a second laparotomy on the
21st postsurgical day revealed a dense, thick, glue-like mass
involving the small intestine and transverse colon. The biopsy
revealed foreign body granulomas. The patient underwent
colectomy and anastomosis. An iatrogenic tear in the trans-
verse colon led to feculent peritonitis resulting in death.
In a case series of three patients, all developed abdominal
fluid collection with fever, signs of peritonitis, and raised
neutrophil counts within 4–7 days after receiving Seprafilm
during laparotomy [47]. All three underwent laparotomy
and a cloudy ascitic fluid was seen in each case. Copious
washing of the abdominal fluid in each case was followed
by improvement in the patient’s condition.
A paradoxical inflammatory reaction to Seprafilm was
attributed to extensive adhesion formation early in the post-
operative period in a 70-year-old woman who had undergone
a low anterior resection [48]. Exploratory surgery on postop-
erative day 11 revealed extensive dense adhesions involving
the abdominal wall, omentum, and small bowel. Pathology
revealed diffuse inflammation with multiple giant cells sug-
gesting a foreign body reaction. The authors conclude that
reports of this kind are uncommon.
Collections of sterile intra-abdominal fluids were identified
in three subjects following the use of Seprafilm in colorectal
surgery [49]. The subjects of each received 2 or 3 sheets of
Seprafilm. Two to 3 weeks later, they were thought to have a
possible abscess or had a slow postoperative course. A CT
scan identified the fluid which was later determined to be a
sterile collection.
Cost-effectiveness
Notwithstanding the repeated reports of clinical efficacy of
Seprafilm described previously in the review, many hospital
and health care administrators have remained unconvinced
of the value of routine use of anti-adhesion adjuvants. Bristow
and colleagues addressed this issue in a cost-effectiveness
analysis of women with stage 1B cervical cancer undergoing
a radical hysterectomy with pelvic lymphadenectomy, in the
presence or absence of Seprafilm [50]. The authors utilized a
decision analysis model, incorporating factors identified by
the Panel on Cost-Effectiveness in Health and Medicine,
which was convened by the US Public Health Service. Clin-
ical assumptions were based on Phase III trials where avail-
able, and otherwise on Phase II trials, retrospective case series
and case reports. Use of Seprafilm in these models was effi-
cacious both in term of cost to society (incremental cost of
non-use $1,112 per patient, with greater quality adjusted life
years), as well as cost to third party payers (incremental cost of
non-use $383 per patient, with greater quality adjusted life
years). The authors conclude that “an adhesion prevention
strategy utilizing Seprafilm in patients undergoing radical
hysterectomy and pelvic lymphadenectomy for Stage 1B cer-
vical cancer, as well as other similar procedures, is cost
effective from both the perspective of society as a whole and
that of a third party payer.” Furthermore, they conclude that
“With current concerns over the escalating economic burden
of healthcare, straightforward clinical intervention such as the
prevention of adhesion related morbidity, offers a real oppor-
tunity for significant cost savings in health care expenditure.”
Summary
The safety and efficacy of Seprafilm use has been demon-
strated in abdominopelvic surgery. Retrospective analysis
from the result of a randomized controlled trial suggests that
wrapping Seprafilm around a newly created anastomosis
may be associated with an increase in anastomotic leak
related adverse events (fistula, leak, abscess, peritonitis,
and sepsis). Based upon this data, Seprafilm labeling has
been updated to warn against wrapping Seprafilm directly
around a newly created anastomotic suture or staple line.
Additional studies have been undertaken in abdominopelvic
procedures to explore the use of Seprafilm in the presence of
overt infections, malignancy, in pediatric patents, in early
ileostomy closure, laparoscopic surgery, and cesarean sec-
tions. While the results of these studies are interesting,
appropriately designed randomized controlled clinical trials
still need to be conducted. Additionally, the results of one
cost-effectiveness study are encouraging but more investi-
gation is warranted. Also, other future studies are needed to
further delineate the molecular biologic processes leading to
normal peritoneal healing as opposed to adhesion develop-
ment, which would allow targeted interventions to improve
adjuvant efficacy. Such approaches could utilize anti-
adhesion products to physically separate otherwise opposing
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tissue surfaces while also serving as a carrier for the delivery
of drugs and/or biologics to further improve the efficacy of
anti-adhesion adjuvants.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Genzyme Corporation C, MA. Seprafilm Adhesion Barrier package
insert (U.S.)
2. Trew G, Pistofidis G, Pados G, Lower A et al (2011) Gynaeco-
logical endoscopic evaluation of 4% icodextrin solution: a Euro-
pean, multicenter, double-blind, randomized study of the efficacy
and safety in the reduction of de novo adhesions after laparoscopic
gynaecological surgery. Hum Reprod 26(8):2015–2027
3. Becker JM, Dayton MT, Fazio VW et al (1996) Prevention of
postoperative abdominal adhesions by a sodium hyaluronate-
based bioresorbable membrane: a prospective, randomized,
double-blind multicenter study. J Am Coll Surg 183(4):297–306
4. Diamond MP (1996) Reduction of adhesions after uterine myo-
mectomy by Seprafilm membrane (HAL-F): a blinded, prospec-
tive, randomized, multicenter clinical study. Seprafilm Adhesion
Study Group. Fertil Steril 66(6):904–910
5. Fukushima T, Matsuo K, Kusunoki M et al (1999) Clinical Study
of a sodium hyaluronate/carboxymethylcellulose anti-adhesion
membrane in abdominal surgery. Surg Treatment 81:227–233
6. Kawamura H, Yokota R, Yokota K et al (2010) A sodium hyalur-
onate carboxymethylcellulose bioresorbable membrane prevents
postoperative small-bowel adhesive obstruction after distal gas-
trectomy. Surg Today 40(3):223–227
7. Beck DE, Cohen Z, Fleshman JW, Kaufman HS, van Goor H,
Wolff BG (2003) A prospective, randomized, multicenter, con-
trolled study of the safety of Seprafilm adhesion barrier in abdom-
inopelvic surgery of the intestine. Dis Colon Rectum 46(10):1310–
1319
8. Fazio VW, Cohen Z, Fleshman JW et al (2006) Reduction in
adhesive small-bowel obstruction by Seprafilm adhesion barrier
after intestinal resection. Dis Colon Rectum 49(1):1–11
9. Fujii S, Shimada H, Ike H et al (2009) Reduction of postoperative
abdominal adhesion and ileus by a bioresorbable membrane. Hep-
atogastroenterology 56(91–92):725–728
10. Zeng Q, Yu Z, You J, Zhang Q (2007) Efficacy and safety of
Seprafilm for preventing postoperative abdominal adhesion: sys-
tematic review and meta-analysis. World J Surg 31(11):2125–
2131, discussion 2132
11. Beck DE (2008) Seprafilm review and meta-analysis. World J Surg
32(8):1883–1884, author reply 1885
12. Mohri Y, Kusunoki M (2008) Efficacy and safety of seprafilm:
systematic review and meta-analysis. World J Surg 32(8):1886–
1887, author reply 1890–1881
13. Holmdahl L (2008) A misleading meta-analysis of seprafilm.
World J Surg 32(8):1888–1889, author reply 1890–1881
14. Salum MR, Lam DT, Wexner SD et al (2001) Does limited place-
ment of bioresorbable membrane of modified sodium hyaluronate
and carboxymethylcellulose (Seprafilm) have possible short-term
beneficial impact? Dis Colon Rectum 44(5):706–712
15. Kudo FA, Nishibe T, Miyazaki K, Murashita T, Nishibe M, Yasuda
K (2004) Use of bioresorbable membrane to prevent postoperative
small bowel obstruction in transabdominal aortic aneurysm sur-
gery. Surg Today 34(8):648–651
16. Mohri Y, Uchida K, Araki T et al (2005) Hyaluronic acid-
carboxycellulose membrane (Seprafilm) reduces early postopera-
tive small bowel obstruction in gastrointestinal surgery. Am Surg
71(10):861–863
17. Leitao MM Jr, Natenzon A, Abu-Rustum NR et al (2009) Postop-
erative intra-abdominal collections using a sodium hyaluronate-
carboxymethylcellulose (HA-CMC) barrier at the time of laparot-
omy for ovarian, fallopian tube, or primary peritoneal cancers.
Gynecol Oncol 115(2):204–208
18. Tabata T, Kihira T, Shiozaki T et al (2010) Efficacy of a sodium
hyaluronate-carboxycellulose membrane (seprafilm) for reducing
the risk of early postoperative small bowel obstruction in patients
with gynecologic malignancies. Int J Gynecol Cancer 20(1):188–
193
19. Khaitan E, Scholz S, Richards WO (2002) Laparoscopic adhesiol-
ysis and placement of Seprafilm: a new technique and novel
approach to patients with intractable abdominal pain. J Laparoen-
dosc Adv Surg Tech A 12(4):241–247
20. Khaitan L, Scholz S, Houston HL, Richards WO (2003) Results
after laparoscopic lysis of adhesions and placement of seprafilm
for intractable abdominal pain. Surg Endosc 17(2):247–253
21. Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kinoshita K (2006)
A novel instrument and technique for using seprafilm hyaluronic
acid/carboxymethylcellulose membrane during laparoscopic myo-
mectomy. J Laparoendosc Adv Surg Tech A 16(5):497–502
22. Chuang YC, Fan CN, Cho FN, Kan YY, Chang YH, Kang HY
(2008) A novel technique to apply a Seprafilm (hyaluronate-car-
boxymethylcellulose) barrier following laparoscopic surgeries.
Fertil Steril 90(5):1959–1963
23. Shinohara T, Kashiwagi H, Yanagisawa S, Yanaga K (2008) A
simple and novel technique for the placement of antiadhesive
membrane in laparoscopic surgery. Surg Laparosc Endosc Percu-
tan Tech 18(2):188–191
24. Fenton BW, Fanning J (2008) Laparoscopic application of hyalur-
onate/carboxymethylcellulose slurry: an adhesion barrier in a slur-
ry formulation goes where the available sheets cannot. Am J
Obstet Gynecol 199(3):325, e321
25. Ortiz MV, Awad ZT (2009) An easy technique for laparoscopic
placement of Seprafilm. Surg Laparosc Endosc Percutan Tech 19
(5):e181–e183
26. Lipetskaia L, Silver DF (2010) Laparoscopic use of a hyaluronic
acid carboxycellulose membrane slurry in gynecological oncology.
JSLS 14(1):91–94
27. Tang CL, Seow-Choen F, Fook-Chong S, Eu KW (2003) Biore-
sorbable adhesion barrier facilitates early closure of the defunc-
tioning ileostomy after rectal excision: a prospective, randomized
trial. Dis Colon Rectum 46(9):1200–1207
28. Salum M, Wexner SD, Nogueras JJ et al (2006) Does sodium
hyaluronate- and carboxymethylcellulose-based bioresorbable
membrane (Seprafilm) decrease operative time for loop ileostomy
closure? Tech Coloproctol 10(3):187–190, discussion 190–181
29. Kawamura YJ, Kakizawa N, Tan KY et al (2009) Sushi-roll wrap
of Seprafilm for ileostomy limbs facilitates ileostomy closure. Tech
Coloproctol 13(3):211–214
30. Vrijland WW, Tseng LN, Eijkman HJ et al (2002) Fewer intraperito-
neal adhesions with use of hyaluronic acid-carboxymethylcellulose
membrane: a randomized clinical trial. Ann Surg 235(2):193–199
31. van der Wal JB, Iordens GI, Vrijland WW, van Veen RN, Lange J,
Jeekel J (2011) Adhesion prevention during laparotomy: long-term
follow-up of a randomized clinical trial. Ann Surg 253(6):1118–1121
32. Uchida K, Urata H, Mohri Y, Inoue M, Miki C, Kusunoki M
(2005) Seprafilm does not aggravate intraperitoneal septic condi-
tions or evoke systemic inflammatory response. Surg Today 35
(12):1054–1059
256 Gynecol Surg (2012) 9:247–257
33. Bristow RE, Montz FJ (2005) Prevention of adhesion forma-
tion after radical oophorectomy using a sodium hyaluronate-
carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol 99
(2):301–308
34. Tan A, Argenta P, Ramirez R, Bliss R, Geller M (2009) The use of
sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier in
gynecologic malignancies: a retrospective review of outcomes.
Ann Surg Oncol 16(2):499–505
35. Oikonomakis I, Wexner SD, Gervaz P, You SY, Secic M, Giamundo
P (2002) Seprafilm: a retrospective preliminary evaluation of the
impact on short-term oncologic outcome in colorectal cancer. Dis
Colon Rectum 45(10):1376–1380
36. Kusunoki M, Ikeuchi H, Yanagi H et al (2005) Bioresorbable
hyaluronate-carboxymethylcellulose membrane (Seprafilm) in sur-
gery for rectal carcinoma: a prospective randomized clinical trial.
Surg Today 35(11):940–945
37. Hayashi S, Takayama T, Masuda H et al (2008) Bioresorbable
membrane to reduce postoperative small bowel obstruction in
patients with gastric cancer: a randomized clinical trial. Ann Surg
247(5):766–770
38. Park CM, Lee WY, Cho YB et al (2009) Sodium hyaluronate-
based bioresorbable membrane (Seprafilm) reduced early postop-
erative intestinal obstruction after lower abdominal surgery for
colorectal cancer: the preliminary report. Int J Colorectal Dis 24
(3):305–310
39. Mizuno R, Yamazaki Y, Hara A, Ashizuka S, Yoshizawa J, Kuwajima
S (2000) Experience with the use of synthetic absorbable anti-
adhesion material (Seprafilm) in pediatric laparotomy. J New Reme-
dies Clin 49(4)
40. Ong TH (2001) Prevention of intraabdominal adhesions in Kasai
portoenterostomy. J Pediatr Surg 36(11):1613–1614
41. Inoue M, Uchida K, Miki C, Kusunoki M (2005) Efficacy of Sepra-
film for reducing reoperative risk in pediatric surgical patients under-
going abdominal surgery. J Pediatr Surg 40(8):1301–1306
42. Winfield RD, Ang DN, Chen MK, Kays DW, Langham MR Jr,
Beierle EA (2007) The use of Seprafilm in pediatric surgical
patients. Am Surg 73(8):792–795
43. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H (2005) Efficacy
of Seprafilm as an adhesion prevention barrier in Cesarean sec-
tions: availability of anti-adhesion film (Seprafilm) for Cesarean
section. Obstetric and Gynecological Treatment [Japanese] 91
(5):557–561, Special Edition
44. Tsuji S, Takahashi K, Yomo H et al (2005) Effectiveness of anti-
adhesion barriers in preventing adhesion after myomectomy in
patients with uterine leiomyoma. Eur J Obstet Gynecol Reprod
Biol 123(2):244–248
45. Klingler PJ, Floch NR, Seelig MH, Branton SA, Wolfe JT,
Metzger PP (1999) Seprafilm-induced peritoneal inflammation: a
previously unknown complication. Report of a case. Dis Colon
Rectum 42(12):1639–1643
46. Trickett JP, Rainsbury RM, Green R (2001) Paradoxical outcome
after use of hyaluronate barrier to prevent intra-abdominal adhe-
sions. J R Soc Med 94(4):183–184
47. Remzi FH, Oncel M, Church JM, Senagore AJ, Delaney CP, Fazio
VW (2003) An unusual complication after hyaluronate-based bio-
resorbable membrane (Seprafilm) application. Am Surg 69
(4):356–357
48. David M, Sarani B, Moid F, Tabbara S, Orkin BA (2005) Para-
doxical inflammatory reaction to Seprafilm: case report and review
of the literature. South Med J 98(10):1039–1041
49. Tyler J, McDermott D, Levoyer T (2008) Sterile intra-abdominal
fluid collection associated with seprafilm use. Am Surg 74
(11):1107–1110
50. Bristow R, Santillan A, Diaz-Montes T, Gardner G, Giuntoli R,
Peeler S (2007) Prevention of adhesion formation after radical hys-
terectomy using a sodium hyaluronate-carboxymethylcellulose (HA-
CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol 104
(3):739–746
Gynecol Surg (2012) 9:247–257 257
